BPH Global Ltd (ASX: BP8)
Health Care · Biotechnology · AU
AU$0.00
+100.00% today · 0.0% 1Y
BPH Global Ltd (ASX: BP8) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.34M and employs 31 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores BPH Global Ltd across four factors: quality 16/100, value 76/100, growth 100/100. Its strongest factor is growth.
BP8 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.34M
- Revenue (TTM)
- $1.15M
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.58
- 52-week high
- AU$0.00
- 52-week low
- AU$0.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.35B
- Employees
- 31
- Next earnings
- —
About BPH Global Ltd
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. The company's diverse product range features both unprocessed and refined bird's nest offerings, alongside marine botanicals like Caulerpa Lentillifera (sea grapes) and various seaweeds. These products are utilized across multiple industries, including food, nutrition, healthcare, dietary supplements, cosmetics, and personal care. Headquartered in Melbourne, Australia, the company was founded in 1984 and transitioned to its current name, BPH Global Ltd, in June 2023, having previously been known as Stemcell United Limited.
- ISIN
- AU0000284366
- Founded
- 1984
- Listed since
- Jun 13, 2000
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.55 | +0.22% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.91 | -4.94% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.